La société de biotechnologie Neovacs, en partenariat avec la société d'investissement Industry et le family office Cofilux-Secufund, ont présenté un plan de reprise de la société Famar Lyon afin de créer un acteur de référence de l'industrie pharmaceutique en France. Leur plan prévoit un investissement global de 37 millions d'euros…..
Trend Chart On Innovative Bioindustries - June 2020, 23rd FEATURE STORY ● Draft landscape of COVID-19 candidate vaccines This landscape document (published on June 16th) has been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 global of the novel coronavirus. Inclusion of any particular product…..
Rigenerand receives regulatory approval for gene therapy production in Italy The italian biotech company Rigenerand has received received authorization from the Italian Medicine Authority (AIFA) to produce gene therapy medicinal products for clinical purposes. This approval enables Rigenerand to manufacture its own product, RR001, for the treatment of pancreatic cancer.…..
Trend Chart On Innovative Bioindustries - June 2020, 2nd FEATURE STORY ● Novartis snags EU nod for SMA gene therapy After a manufacturing-related delay, Novartis has won conditional approval in the EU for Zolgensma®, the one-time gene therapy to treat patients with a clinical diagnosis of SMA type 1 and…..
BioPharmAnalyses and OctopusyX BioConsulting are proud to announce the launch of their latest report:"AAV-based gene therapy Products: Ongoing Clinical Trials". This 205-page report provides you with a unique exhaustive overview of 116 ongoing trials for the treatment of 40 diseases (as of June 2020). More than 80 products from 49…..
A point of care center to be established in Madrid for the development of T-cell and dendritic cell-based therapies
A point of care center to be established in Madrid for the development of T-cell and dendritic cell-based therapies Orgenesis, a global US biotech company developing personalized therapies and closed processing systems through its Cell & Gene Therapy (CGT) Biotech Platform, announced a research and development collaboration with Hospital Infantil…..
Asklepios BioPharmaceutical (AskBio) has acquired BrainVectis, a French company dedicated to the development of gene therapy for neurodegenerative disorders. Founded in 2015, BrainVectis is a spin-off from French national institute for health and medical research (INSERM). Based on work carried out by Nathalie Cartier-Lacave and her team and collaborators…..
Trend Chart on Innovative Bioindustries April 12th FEATURE STORY ● Sirnaomics releases positive interim data from phase II Trial of siRNA candidate studies Sirnaomics, a US-China RNAi therapeutics company, reported on April 9th positive interim results from a Phase II trial of its RNA treatment for non-melanoma skin cancer. STP705…..
Covid-19 et remdesivir : Lettre ouverte de Daniel O’Day, CEO de Gilead Sciences 4 avril 2020. Au cours de la semaine dernière, Gilead a travaillé, en collaboration avec les autorités de santé, à la mise en place de programmes d'accès complémentaires pour mettre à disposition des patients, notre médicament expérimental…..
Remdesivir and Covid-19: an update from Daniel O'Day, chairman and CEO of Gilead April 04, 2020. Over the course of the past week, Gilead has been working in consultation with regulatory authorities to establish additional expanded access programs for remdesivir, our investigational medicine for COVID-19. The programs enable hospitals or…..